In phase I and II studies initiated by researchers from the Medical University of Warsaw, local injection of substance P labelled with 213Bi/225Ac in the case of patients with relapsed glioblastoma provides satisfactory results with prolongation of survival parameters compared to standard treatment [3, 5, 6]. This evidence concerns the gene TAC1 and glioblastoma.